Latest Class Action

Investigation – Redbox Entertainment acquisition Investigation – Singularity Future Technology Teladoc Health Alert – Class Action Investigation IonQ – Class Action Investigation – Possible Securities Law Violations Class Action Lawsuit – IronNet, Inc. Class Action Investigation – Pulse Biosciences, Inc. Class Action Investigation – Amazon.com, Inc. Class Action Investigation – Arqit Quantum Inc.

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX

NEW YORK (ClassActionDaily) The Rosen Law Firm released the following:

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations that Cortexyme may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Cortexyme securities you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.  The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to http://www.rosenlegal.com/cases-register-2254.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On October 26, 2021, aftermarket hours, Cortexyme issued a press release “report[ing] top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis).”  The press release reported, in relevant part, that the study had failed to meet statistical significance in its co-primary endpoints of improving cognitive and functional abilities in patients with mild-to-moderate Alzheimer’s disease.

On this news, Cortexyme’s stock price fell $44.17 per share, or 76%, to close at $13.51 per share on October 27, 2021, damaging investors.

Then, on January 26, 2022, before market hours, Cortexyme disclosed receipt of a letter from the U.S. Food and Drug Administration (“FDA”) advising that the FDA had “plac[ed] a full clinical hold on atuzaginstat’s (COR388) Investigational New Drug application (IND 134303).”

On this news, Cortexyme’s stock price fell $2.85 per share, or 31%, to close at $6.21 per share on January 26, 2022, further damaging investors.

On February 1, 2022, Cortexyme issued a press release announcing plans to reduce its workforce by 53% in response to the clinical hold.  That same day, Cortexyme announced the resignations of Casey Lynch, the Company’s CEO and Chair of the Board, and Steve Dominy, the Company’s Chief Scientific Officer and a director.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.  Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.  Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.  Rosen Law Firm has achieved the largest-ever securities class action settlement against a Chinese Company.  Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for a number of securities class action settlements in 2017.  The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors.  In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar.  Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com